Lantern Pharma Inc. (NASDAQ:LTRN) Q3 2024 Results Conference Call November 7, 2024 4:30 PM ET Company Participants Panna Sharma - President and CEO David Margrave - Chief Financial Officer Kishor Bhatia - Chief Scientific Officer Operator Good afternoon, and welcome to our Third Quarter 2024 earnings call. As a reminder, this call is being recorded, and all attendees are in a listen-only mode. We will open the call for questions-and-answers after our management's presentation. A webcast replay of today's co ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Delaware 001-39318 46-3973463 (State or Other Jurisdiction (Commission (IRS Employer of Incorporation) File Number) Identification No.) 1920 McKinney Avenue, 7th Floor Dallas, Texas 75201 (Address of Principal Executive Offices) (Zip Code) Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.0001 par value LTRN The Nasdaq Stock Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 ...

Exhibit 99.1 Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates ■ Lantern is advancing three AI-guided precision-oncology drug candidates in active Phase 1 and Phase 2 clinical trials, while evaluating additional ADC-based preclinical molecules for development. ■ Preliminary patient data and clinical readouts for the Phase 2 LP-300 Harmonic™ Trial showed an 86% clinical benefit rate in the initial 7 patient lead-in cohort, and additional patients continue to be enrolled in the ...

Second Quarter 2024 Operating & Financial Results Conference Call / Webinar NASDAQ :LTRN With additional focus on preliminary patient data and clinical readouts for Phase 2 LP-300 Harmonic Trial August 8th, 2024 4:30 PM Eastern Time Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other ...

Lantern Pharma Inc. (NASDAQ:LTRN) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Panna Sharma - President and CEO David Margrave - Chief Financial Officer Dr. Reggie Ewesuedo - Vice President, Clinical Development Conference Call Participants John Vandermosten - Zacks Research Operator Good afternoon. And welcome to our Second Quarter 2024 Earnings Call. As a reminder, this call is being recorded and all attendees are in a listen-only mode. We will open the call for question ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | |-------------------------------------------------------------------------------------------------------------------------------|----------------------------------------- ...

Exhibit 99.1 Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates ● Active clinical trials across three AI-guided drug candidates with additional ADC-based preclinical molecules in evaluation for development. ● Preliminary patient data and clinical readouts for Phase 2 LP-300 Harmonic™ Trial released showing an 86% clinical benefit rate in the initial 7 patient safety lead-in cohort. ● Issued a Certificate of Patent by the Japanese Patent Office directed to Lantern Pharma's drug ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delaware 001-39318 46-3973463 (State or Other Jurisdiction (Commission (IRS Employer of Incorporation) File Number ...

Exhibit 99.1 Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights ● Active clinical trials across three AI-guided drug candidates with initial data and clinical readouts for LP-184 on- track for the second half of 2024. ● Obtained regulatory allowance to begin Phase 2 Harmonic™ clinical trial enrollment in Japan and Taiwan where approximately 30-35+% of all lung cancer cases occur in never-smokers with NSCLC; Harmonic™ continues patient enrollment in the US. ● Phase 1 clinical ...

Lantern Pharma Inc. (NASDAQ:LTRN) Q4 2023 Earnings Conference Call March 18, 2024 4:30 PM ET Company Participants Panna Sharma - President and Chief Executive Officer David Margrave - Chief Financial Officer Conference Call Participants Operator Good afternoon, and welcome to our Fourth Quarter and Year End 2023 Earnings Call. As a reminder, this call is being recorded and all attendees are in a listen-only mode. We will open the call for questions and answers after our management’s presentation. A webcast ...